Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Long-term (>48 weeks) safety and tolerability of erenumab in real-life — Cinzia Aurilia (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Long-term (>48 weeks) safety and tolerability of erenumab in real-life
Shared by
Massimo Filippi
Long-term (>48 weeks) safety and tolerability of erenumab in real-life
Article
2021
en
Authors
+30 more
CA
Cinzia Aurilia
GE
Gabriella Egeo
LF
Luisa Fofi
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2021
Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study
Cinzia Aurilia
,
Sabina Cevoli
,
Gabriella Egeo
,
Luisa Fofi
,
Roberta Messina
,
Antonio Salerno
,
Paola Torelli
,
Maria Albanese
,
Antonio Carnevale
,
Francesco Bono
,
Domenico D’Amico
,
Massimo Filippi
,
Claudia Altamura
,
Fabrizio Vernieri
,
Bruno Colombo
,
Fabio Frediani
,
B. Mercuri
,
Florindo d’Onofrio
,
Licia Grazzi
,
Marco Aguggia
,
Valentina Favoni
,
Cinzia Finocchi
,
Paola Di Fiore
,
Carlemina Maria Costa
,
Nicoletta Brunelli
,
Adriana Fallacara
,
Davide Bertuzzo
,
Maurizio Zucco
,
Laura Di Clemente
,
Michele Trimboli
,
Angelo Pascarella
,
Lucia Manzo
,
Piero Barbanti
Article
2021
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Piero Barbanti
,
Cinzia Aurilia
,
Sabina Cevoli
,
Gabriella Egeo
,
Luisa Fofi
,
Roberta Messina
,
Antonio Salerno
,
Paola Torelli
,
Maria Albanese
,
Antonio Carnevale
,
Francesco Bono
,
Domenico D’Amico
,
Massimo Filippi
,
Claudia Altamura
,
Fabrizio Vernieri
Article
2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti
,
Gabriella Egeo
,
Stefania Proietti
,
Florindo d’Onofrio
,
Cinzia Aurilia
,
Cinzia Finocchi
,
Laura Di Clemente
,
Maurizio Zucco
,
Alberto Doretti
,
Stefano Messina
,
Massimo Autunno
,
Angelo Ranieri
,
Antonio Carnevale
,
Bruno Colombo
,
Massimo Filippi
,
Miriam Tasillo
,
Steno Rinalduzzi
,
Pietro Querzani
,
Giuliano Sette
,
Lorenzo Forino
,
Francesco Zoroddu
,
Corrigendum
2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti
,
Gabriella Egeo
,
Stefania Proietti
,
Florindo d’Onofrio
,
Cinzia Aurilia
,
Cinzia Finocchi
,
Laura Di Clemente
,
Maurizio Zucco
,
Alberto Doretti
,
Stefano Messina
,
Massimo Autunno
,
Angelo Ranieri
,
Antonio Carnevale
,
Bruno Colombo
,
Massimo Filippi
,
Miriam Tasillo
,
Steno Rinalduzzi
,
Pietro Querzani
,
Giuliano Sette
,
Lorenzo Forino
,
Francesco Zoroddu
,
Article
2025
Observational, Multicenter study on long-term Effectiveness and tolerability of aliROcumab (OMERO): an Italian real-life experience
Alberico L. Catapano
,
Aldo P. Maggioni
,
Francesco Rossi
,
Eleonora Consolo
,
Lucia Notarianni
,
Giancarlo Agnelli
Micaela Robotti
,
Alessandro Valenza
,
Cecilia Camarda
,
L. Borrello
,
Marco Aguggia
,
Giovanna Viticchi
,
Carlo Tomino
,
Giulia Fiorentini
,
Bianca Orlando
,
Stefano Bonassi
,
Paola Torelli
Micaela Robotti
,
Alessandro Valenza
,
Cecilia Camarda
,
L. Borrello
,
Marco Aguggia
,
Giovanna Viticchi
,
Carlo Tomino
,
Giulia Fiorentini
,
Bianca Orlando
,
Stefano Bonassi
,
Paola Torelli
Discussion(0)
No comments yet. Be the first to comment.